Renoprotective effect of carbamylated darbepoetin and udenafil in ischemia-reperfusion of rat kidney due to the effect of preconditioning and inhibition of nuclear factor kappa B
Авторы
-
Darya A. Kostina
Belgorod State National Research University
https://orcid.org/0000-0002-4505-3988
- Tatiana G. Pokrovskaya Belgorod State National Research University
- Vladimir Y. Poltev Belgorod State National Research University
DOI:
https://doi.org/10.3897/rrpharmacology.7.63059Аннотация
Introduction: Acute kidney injury is a widespread complication in hospitalized patients, with a high mortality rate and long-term complications affecting prognosis and quality of life and with high human and financial costs. In addition, to date, no clear algorithm for the prevention of this type of damage has been developed.
Materials and methods: The research was carried out on male Wistar rats. A 40-minute renal ischemia-reperfusion model was used to model acute kidney injury. Further, the renoprotective properties of carbamylated darbepoetin, udenafil and their combination were assessed based on the analysis of the biochemical studies’ results, dynamics of the renal status and the renal microvasculature, and the pathomorphological picture. A series of experiments was also carried out to assess the contribution of adenosine triphosphate-dependent potassium channels and nuclear factor kappa B to the renoprotective properties of the said agents.
Results and discussion: Prophylactic administration of carbamylated darbepoetin at a dose of 50 μg/kg and udenafil at a dose of 8.7 mg/kg led to a statistically significant decrease in creatinine and blood urea nitrogen, an increase in glomerular filtration rate with a simultaneous decrease in fractional excretion of sodium, as well as an increase in the level of microcirculation in the kidneys and a decrease in the severity of damage according to the data of a pathomorphological examination at all time points of the experiment. A higher efficiency of correcting ischemic and reperfusion renal injuries was observed when using a combination of the said pharmacological agents. A series of experiments with glibenclamide demonstrated that its preliminary administration levels the renoprotective properties of carbamylated darbepoetin and udenafil. The ability of the studied pharmacological agents to reduce lipopolysaccharide-induced expression of nuclear factor kappa B in mononuclear cells was also demonstrated. The results of the research suggest that the renoprotective effects of carbamylated darbepoetin, udenafil, and their combination are realized through ATP-dependent potassium channels and nuclear factor kappa B.
Conclusion: Pharmacological preconditioning with carbamylated darbepoetin and udenafil reduces the severity of acute kidney injury induced by ischemia-reperfusion.
Ключевые слова:
acute kidney injury, carbamylated darbepoetin, ischemia-reperfusion, nuclear factor kappa B, preconditioning, udenafilБиблиографические ссылки
• Abu Jawdeh BG, Govil A (2017) Acute kidney injury in transplant setting: differential diagnosis and impact on health and health care. Advances in Chronic Kidney Disease 24(4): 228–232. https://doi. org/10.1053/j.ackd.2017.05.005 [PubMed]
• Agarwal R (2018) Mechanisms and mediators of hypertension in¬duced by erythropoietin and related molecules. Nephrology Dial¬ysis Transplantation 33(10): 1690–1698. https://doi.org/10.1093/ ndt/gfx324
• An JY, Ball MW, Gorin MA, Hong JJ, Johnson MH, Pavlovich CP, Allaf ME, Pierorazio PM (2017) Partial vs radical nephrectomy for T1-T2 renal masses in the elderly: comparison of complications, renal function, and oncologic outcomes. Urology 100: 151–157. https://doi.org/10.1016/j.urology.2016.10.047 [PubMed] [PMC]
• Basile DP, Anderson MD, Sutton TA (2012) Pathophysiology of acute kidney injury. Comprehensive Physiology 2(2): 1303–1353. https://doi.org/10.1002/cphy.c110041 [PubMed] [PMC]
• Bhargava P, Schnellmann RG (2017) Mitochondrial energetics in the kidney. Nature Reviews. Nephrology 13(10): 629–646. https:// doi.org/10.1038/nrneph.2017.107 [PubMed] [PMC]
• Bhoopalan SV, Huang LJ, Weiss MJ (2020) Erythropoietin regula¬tion of red blood cell production: from bench to bedside and back. F1000Research 9 (Faculty Rev): e1153. https://doi.org/10.12688/ f1000research.26648.1 [PubMed] [PMC]
• Bonventre JV, Yang L (2011) Cellular pathophysiology of ischemic acute kidney injury. The Journal of Clinical Investigation 121(11): 4210–4221. https://doi.org/10.1172/JCI45161 [PubMed] [PMC]
• Brines M, Cerami A (2008) Erythropoietin mediated tissue pro¬tection: reducing collateral damage from the primary injury re¬sponse. Journal of Internal Medicine 264(5): 405–432. https://doi. org/10.1111/j.1365-2796.2008.02024.x [PubMed]
• Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A (2004) Erythropoietin mediates tis¬sue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America 101(41): 14907–14912. https://doi. org/10.1073/pnas.0406491101 [PubMed] [PMC]
• Cho MC, Paick JS (2014) Udenafil for the treatment of erectile dys¬function. Therapeutics and Clinical Risk Management 10: 341–354. https://doi.org/10.2147/TCRM.S39727 [PubMed] [PMC]
• Collino M, Thiemermann C, Cerami A, Brines M (2015) Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engi¬neered from erythropoietin. Pharmacology & Therapeutics 151: 32–40. https://doi.org/10.1016/j.pharmthera.2015.02.005 [PubMed]
• Danilenko LM (2015) The role of mitochondrial ATF-dependent potassium channels in the cardioprotective effect of nicorandil on the model of coronary occlusive myocardial infarction. Research Result. Medicine and Pharmacy Series [Nauchnyy Rezul’tat. Seri¬ya Meditsina i Farmatsiya] 4(6): 40–44. [in Russian] https://doi. org/10.18413/2313-8955-2015-1-4-40-44
• Diao M, Qu Y, Liu H Ma Y, Lin X (2019) Effect of carbamylated erythropoietin on neuronal apoptosis in fetal rats during intrauterine hypoxic-ischemic encephalopathy. Biological Research 52(1): 1–28. https://doi.org/10.1186/s40659-019-0234-7 [PubMed] [PMC]
• Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH, Kim WB (2002) Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Archives of Pharmacal Research 25(6): 873–878. https://doi.org/10.1007/BF02977007 [PubMed]
• Dryazhenkov IG, Komlev DL, Los’ MS (2013) Factors of ischemic lesions in the kidney and its resection. Сlinical Medicine [Klinich¬eskaya Meditsina] 6: 21–24. [in Russian]
• Dube S, Matam T, Yen J, Mang HE, Dagher PC, Hato T, Sutton TA (2017) Endothelial STAT3 modulates protective mechanisms in a mouse ischemia-reperfusion model of acute kidney injury. Journal of Immunology Research 2017: e4609502. https://doi. org/10.1155/2017/4609502 [PubMed] [PMC]
• Elliott S, Tomita D, Endre Z (2017) Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrology 18(1): 1–14. https://doi.org/10.1186/s12882-017-0438-4 [PubMed] [PMC]
• Erol B, Turker T, Tok A, Bektas S, Mungan G, Ozkanli S, Karakas B, Tokgoz H, Akduman B, Mungan A (2015) The protective effects of tadalafil on renal damage following ischemia reperfusion injury in rats. The Kaohsiung Journal of Medical Sciences 31(9): 454–462. https://doi.org/10.1016/j.kjms.2015.06.005 [PubMed]
• Han SJ, Lee HT (2019) Mechanisms and therapeutic targets of isch¬emic acute kidney injury. Kidney Research and Clinical Practice 38(4): 427–440. https://doi.org/10.23876/j.krcp.19.062 [PubMed] [PMC]
• Johnson FL, Patel NSA, Purvis GSD, Chiazza F, Chen J, Sordi R, Hache G, Merezhko VV, Collino M, Yaqoob MM, Thiemermann C (2017) Inhibition of IκB kinase at 24 hours after acute kidney injury improves recovery of renal function and attenuates fibrosis. Jour¬nal of the American Heart Association 6(7): e005092. https://doi. org/10.1161/JAHA.116.005092 [PubMed] [PMC]
• Kaplin AN, Pokrovskiy MV Korokin MV (2013) Comparison of cardi¬oprotective properties of erythropoietin and cyclosporine in ischemic and reperfusion injury. Kuban Scientific Medical Bulletin [Kubanskii Nauchnyy Meditsinskii Vestnik] 7(142): 191–193 [in Russian]
• KDIGO [AKI Work Group] (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements 2(1): 1–138.
• Kebschull L, Theilmann LFC, Mohr A, Uennigmann W, Stoeppeler S, Heitplatz B, Spiegel HU, Bahde R, Palmes DM, Becker F (2017) EPOR2/βcR2-independendent effects of low-dose epoetin-α in por¬cine liver transplantation. Bioscience Reports 37(6): BSR20171007. https://doi.org/10.1042/BSR20171007 [PubMed] [PMC]
• Kezić A, Stajic N, Thaiss F (2017) Innate immune response in kidney ischemia/reperfusion injury: Potential target for therapy. Journal of Immunology Research 2017: e6305439. https://doi. org/10.1155/2017/6305439 [PubMed] [PMC]
• Kolesnichenko PD, Popova IA, Sheblykin DV, Aldeen Azeez AM, Soldatov VO, Povetkin SV, Lazareva GA, Stepchenko AA (2019) Carbamylated darbepoetin in combination with ethoxydol attenuates doxorubicin-induced cardiomyopathy in rats. EurAsian Journal of BioSciences 13(2): 957–963.
• Kolesnik IM, Lazarenko VA, Pokrovskiy MV (2015) Assessment of the impact of pharmacological preconditioning with recombinant erythropoietin on the state of the resected liver in experiment. Kursk Scientific and Practical Bulletin “Man and Health” [Kurskii Nauch¬no-Prakticheskii Vestnik ”Chelovek i Ego Zdorov’e”] (2): 74–78. [in Russian]
• Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C (2009) PDE5 inhibitors: in vitro and in vivo pharmacological profile. Current Pharmaceutical Design 15(30): 3464–3475. https://doi. org/10.2174/138161209789206971 [PubMed]
• Kuhrt D, Wojchowski DM (2015) Emerging EPO and EPO recep¬tor regulators and signal transducers. Blood 125(23): 3536–3541. https://doi.org/10.1182/blood-2014-11-575357 [PubMed] [PMC]
• Makris K, Spanou L (2016) Acute kidney injury: definition, patho¬physiology and clinical phenotypes. The Clinical Biochemist Re-views 37(2): 85–98. [PubMed] [PMC]
• Maringer K, Sims-Lucas S (2016) The multifaceted role of the renal microvasculature during acute kidney injury. Pediatric Nephrolo-gy (Berlin, Germany) 31(8): 1231–1240. https://doi.org/10.1007/ s00467-015-3231-2 [PubMed] [PMC]
• Moore PK, Hsu RK, Liu KD (2018) Management of acute kidney injury: core curriculum 2018. American Journal of Kidney Diseases 72(1): 136–148. https://doi.org/10.1053/j.ajkd.2017.11.021 [PubMed]
• Nam JK, Kim JH, Park SW, Chung MK (2020) The association of phosphodiesterase 5 inhibitor on ischemia-reperfusion induced kidney injury in rats. Urology Journal 17(1): 91–96. https://doi. org/10.22037/uj.v0i0.4173 [PubMed]
• Park KM, Byun JY, Kramers C, Kim JI, Huang PL, Bonventre JV (2003) Inducible nitric-oxide synthase is an important contribu¬tor to prolonged protective effects of ischemic preconditioning in
• the mouse kidney. The Journal of Biological Chemistry 278(29): 27256–27266. https://doi.org/10.1074/jbc.M301778200 [PubMed]
• Peresypkina AA, Pokrovskii MV, Gubareva VO, Dolzhikov AA (2018) Protective effect of carbamylated darbepoetin on the model of ischemic neuropathy of the optic nerve in rats. Experimental and Clinical Phar¬macology [Eksperimental’naya i Klinicheskaya Farmakologiya] 81(7): 8–13. https://doi.org/10.30906/0869-2092-2018-81-7-8-13 [in Russian]
• Reznikov K, Gorbunova N, Kolesnichenko P, Tverskoy A, Kostina D, Bashkatova D, Nikitina V (2017) Search of new pharmaceuti-cals on the basis of darbepoetin in the treatment of ischemic stroke (review of literature). Research Results in Pharmacology 3(1): 125– 136. https://doi.org/10.18413/2500-235X-2017-3-1-125-136
• Rivera-Cervantes MC, Jarero-Basulto JJ, Murguía-Castillo J, Marín- López AG, Gasca-Martínez Y, Cornelio-Martínez S, Beas-Zárate C (2019) The recombinant human erythropoietin administered in neo¬natal rats after excitotoxic damage induces molecular changes in the hippocampus. Frontiers in Neuroscience 13: e118. https://doi. org/10.3389/fnins.2019.00118 [PubMed] [PMC]
• Sedaghat Z, Kadkhodaee M, Seifi B, Salehi E (2019) Inducible and endothelial nitric oxide synthase distribution and expres¬sion with hind limb per-conditioning of the rat kidney. Archives of Medical Science 15(4): 1081–1091. https://doi.org/10.5114/ aoms.2019.85651 [PubMed] [PMC]
• Shabelnikova A (2016) Correction of ischemic damage to the retina on application of pharmacological preconditioning of recombinant erythropoietin. Research Results in Pharmacology 2(2): 67–90. https://doi.org/10.18413/2313-8971-2016-2-2-67-90
• Shirokova OM, Sokolov RA, Korotchenko SA, Pershin VI, Ermin KV, Glyavina MM, Zhuchenko M, Andreeva NN, Shchelchkova NA, Mukhina IV (2019) Neurotropic effect of carbamylated dar¬bepoietin on the model of primary hippocampal culture. Modern Technologies in Medicine [Sovremennye Tekhnologii v Meditsine] 11(4): 87–93. https://doi.org/10.17691/stm2019.11.4.10
• Silver SA, Chertow GM (2017) The economic consequences of acute kidney injury. Nephron 137(4): 297–301. https://doi. org/10.1159/000475607 [PubMed] [PMC]
• Tasanarong A, Duangchana S, Sumransurp S, Homvises B, Sat¬dhabudha O (2013) Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, dou-ble-blind controlled trial. BMC Nephrology 14: e136. https://doi. org/10.1186/1471-2369-14-136 [PubMed] [PMC]
• Tverskoi A, Kolesnichenko P, Shcheblykina O, Gorbunova N, Mo¬rozov V, Mukhina T (2018) Morphology of the rat’s brain in four vessels model of ischemic stroke after administration of carbamylat¬ed darbepoetin. Drug Invention Today 10(5): 3897–3900.
• Vázquez-Méndez E, Gutiérrez-Mercado Y, Mendieta-Condado E, Gálvez-Gastélum FJ, Esquivel-Solís H, Sánchez-Toscano Y, Mo-rales-Martínez C, Canales-Aguirre AA (2020) Recombinant eryth¬ropoietin provides protection against renal fibrosis in adenine-in-duced chronic kidney disease. Mediators of Inflammation 2020: e8937657. https://doi.org/10.1155/2020/8937657
• Wang W, Mitra A, Poole B, Falk S, Lucia MS, Tayal S, Schrier R (2004) Endothelial nitric oxide synthase-deficient mice exhibit in-creased susceptibility to endotoxin-induced acute renal failure. American Journal of Physiology-Renal Physiology 287(5): F1044– F1048. https://doi.org/10.1152/ajprenal.00136.2004
• Watowich SS (2011) The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. Journal of Investiga¬tive Medicine: the Official Publication of the American Federation for Clinical Research 59(7): 1067–1072. https://doi.org/10.2310/JIM.0b013e31820fb28c [PubMed] [PMC]
• Yamasowa H, Shimizu S, Inoue T, Takaoka M, Matsumura Y (2005) Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. The Journal of Pharmacology and Ex¬perimental Therapeutics 312(1): 153–159. https://doi.org/10.1124/ jpet.104.074427 [PubMed]
• Zahran MH, Barakat N, Khater S, Awadalla A, Mosbah A, Nabeeh A, Hussein AM, Shokeir AA (2019) Renoprotective effect of lo¬cal sildenafil administration in renal ischaemia-reperfusion injury: A randomised controlled canine study. Arab Journal of Urology 17(2): 150–159. https://doi.org/10.1080/2090598X.2019.1600995 [PubMed] [PMC]
• Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, Paick JS, Ahn TY, Min KS, Park K, Park JK (2011) Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. European Urology 60(2): 380–387. https://doi. org/10.1016/j.eururo.2011.03.025 [PubMed]
• Zubareva EV, Nadezhdin SV, Burda YE, Nadezhdina NA, Gashevskaya AS (2019) Pleiotropic effects of Erythropoietin. Influence of Erythropoietin on processes of mesenchymal stem cells differen¬tiation. Research Results in Pharmacology 5(1): 53–66. https://doi.org/10.3897/rrpharmacology.5.33457
Русский
English
